010 Real-world experience with ocrelizumab in the MSBase registry – Australian RRMS cohort

• Mark Slee,
• Suzanne Hodgkinson,
• Ernest Butler,
• Tim Spelman,
• Helmut Butzkueven,
• Jeanette Lechner-Scott,
• Richard Macdonell,
• Anneke Van Der Walt,
• Katherine Buzzard,
• MSBase Study Group,
• Bruno Marcel

Affiliations

Mark Slee

1 Neurology, Flinders Medical Centre, Adelaide, South Australia, Australia

Suzanne Hodgkinson

Liverpool Hospital, Sydney, NSW, Australia

Ernest Butler

40 Monash Medical Centre, Melbourne, Victoria, Australia

Tim Spelman

Public Health, Burnet Institute International Health Research Group, Melbourne, Victoria, Australia

Helmut Butzkueven

Department of Neuroscience, Monash Univeristy, Melbourne, Victoria, Australia

Jeanette Lechner-Scott

1University of Newcastle, Newcastle, NSW, Australia

Richard Macdonell

Austin Health, Heidelberg, VIC, Australia

Anneke Van Der Walt

Royal Melbourne Hospital, Parkville, VIC, Australia

Katherine Buzzard

4Neurosciences, Melbourne Health, Melbourne, VIC, Australia

MSBase Study Group

2MSBase Foundation, Melbourne, VIC, Australia

Bruno Marcel

10Roche Products Pty Ltd, Sydney, NSW, Australia